# MAPT (Microtubule-Associated Protein Tau) — Target Profile ## Overview Microtubule-Associated Protein Tau (MAPT) is central to Alzheimer's disease and tauopathies. Tau stabilizes microtubules but hyperphosphorylation causes aggregation into neurofibrillary tangles. Six isoforms (3R/4R) exist with distinct disease associations. Tau pathology correlates with cognitive decline more strongly than amyloid plaques, making it a prime therapeutic target. **Target class: Structural Protein** — Tau is an intrinsically disordered protein that adopts pathological conformations during disease. While historically challenging to drug, cryo-EM structures of disease-specific tau filament folds have enabled conformation-selective therapeutic approaches. ## Druggability Analysis This target has a **medium druggability** profile. Multiple therapeutic modalities are being explored including anti-tau antibodies, aggregation inhibitors, antisense oligonucleotides (ASOs), and kinase inhibitors targeting tau phosphorylation. **Druggability score:** 0.65 (65th percentile) — Target shows moderate druggability with multiple active clinical programs. ## Clinical Pipeline **Phase 3:** - **LMTX (TRx0237)** — Tau aggregation inhibitor for Alzheimer's disease **Phase 2:** - **Semorinemab** — Anti-tau antibody for Alzheimer's disease - **Bepranemab** — Anti-tau antibody targeting mid-domain tau **Phase 1/Preclinical:** - **Tilavonemab** — Anti-tau antibody (N-terminal) - **BIIB080 (IONIS-MAPTRx)** — Antisense oligonucleotide reducing tau expression ## Structural Biology 134 PDB structures available, including cryo-EM structures of disease-specific tau filament folds. AlphaFold predicted structure also available. Cryo-EM revealed that different tauopathies feature distinct filament conformations, enabling conformation-selective drug design. ## SciDEX Research Context - One of the most studied targets in the neurodegeneration portfolio - Strong knowledge graph connectivity to Alzheimer's disease pathways - Multiple hypotheses in the SciDEX Exchange involve tau-related mechanisms
A major challenge is achieving selectivity between tau isoforms (3R vs 4R tau), as different tauopathies preferentially aggregate specific isoforms; antibody-based therapies can achieve epitope selectivity but small-molecule aggregation inhibitors may lack isoform discrimination. Off-target phosphorylation modulation is a concern, as kinase inhibitors targeting tau phosphorylation regulators may affect multiple kinase pathways with broader CNS effects.
Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.
Relevant trials from ClinicalTrials.gov